- Home
- FRD vs GNLX Comparison
FRD vs GNLX Comparison
Compare FRD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRD | GNLX |
|---|---|---|
| Founded | 1965 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.3M | 133.0M |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FRD | GNLX |
|---|---|---|
| Price | $32.95 | $2.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 101.6K | ★ 199.2K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.79% | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $121,157,278.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.27 | ★ N/A |
| Revenue Growth | ★ 55.82 | N/A |
| 52 Week Low | $14.52 | $2.29 |
| 52 Week High | $37.97 | $8.54 |
Technical Indicators
Market Signals| Indicator | FRD | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 49.49 |
| Support Level | $17.90 | $2.73 |
| Resistance Level | $37.32 | $3.00 |
| Average True Range (ATR) | 2.54 | 0.14 |
| MACD | -0.45 | -0.01 |
| Stochastic Oscillator | 40.80 | 35.80 |
Price Performance
Historical ComparisonAbout FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.